Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1994 Aug;57(8):921–924. doi: 10.1136/jnnp.57.8.921

Vigabatrin and lamotrigine in refractory epilepsy.

I Stolarek 1, J Blacklaw 1, G Forrest 1, M J Brodie 1
PMCID: PMC1073074  PMID: 8057114

Abstract

Epilepsy arises from an imbalance of inhibitory and excitatory influences in the brain. Vigabatrin (VIG) decreases the breakdown of the inhibitory neurotransmitter gamma-aminobutyric acid, whereas lamotrigine (LTG) reduces presynaptic excitatory amino acid release. 22 patients with refractory epilepsy, treated with an anticonvulsant regimen containing VIG, entered a balanced, double blind, placebo controlled, crossover trial of additional LTG. Treatment periods of 12 weeks (25 mg, 50 mg, 100 mg LTG twice daily for four weeks at each dose, and matched placebo) were followed by wash out intervals of four weeks. 14 of the 20 patients completing the study improved, resulting in a significant fall in seizure days and numbers. Analysis of seizure type confirmed a beneficial effect on partial and secondary generalised tonic-clonic seizures. At the highest LTG dose (200 mg daily) there was a median fall of 37% in seizure count with nine (45%) patients reporting > 50% reduction. Three of these patients were seizure free during this month of treatment. Side effects were minimal throughout the study. Concentrations of other antiepileptic drugs, including those of carbamazepine 10,11-epoxide, were not modified by LTG. This study suggests a substantial efficacy for a regimen containing VIG and LTG. Combinations of drugs with complementary modes of action may provide a rational pharmacological approach to the management of refractory epilepsy.

Full text

PDF
921

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Binnie C. D., Debets R. M., Engelsman M., Meijer J. W., Meinardi H., Overweg J., Peck A. W., Van Wieringen A., Yuen W. C. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res. 1989 Nov-Dec;4(3):222–229. doi: 10.1016/0920-1211(89)90007-7. [DOI] [PubMed] [Google Scholar]
  2. Brodie M. J. Lamotrigine. Lancet. 1992 Jun 6;339(8806):1397–1400. doi: 10.1016/0140-6736(92)91207-o. [DOI] [PubMed] [Google Scholar]
  3. Goa K. L., Ross S. R., Chrisp P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1993 Jul;46(1):152–176. doi: 10.2165/00003495-199346010-00009. [DOI] [PubMed] [Google Scholar]
  4. Grant S. M., Heel R. C. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs. 1991 Jun;41(6):889–926. doi: 10.2165/00003495-199141060-00007. [DOI] [PubMed] [Google Scholar]
  5. Jawad S., Richens A., Goodwin G., Yuen W. C. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia. 1989 May-Jun;30(3):356–363. doi: 10.1111/j.1528-1157.1989.tb05309.x. [DOI] [PubMed] [Google Scholar]
  6. Loiseau P., Yuen A. W., Duché B., Ménager T., Arné-Bès M. C. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res. 1990 Nov;7(2):136–145. doi: 10.1016/0920-1211(90)90099-h. [DOI] [PubMed] [Google Scholar]
  7. Macphee G. J., Thompson G. G., Scobie G., Agnew E., Park B. K., Murray T., McColl K. E., Brodie M. J. Effects of cimetidine on carbamazepine auto- and hetero-induction in man. Br J Clin Pharmacol. 1984 Sep;18(3):411–419. doi: 10.1111/j.1365-2125.1984.tb02483.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Matsuo F., Bergen D., Faught E., Messenheimer J. A., Dren A. T., Rudd G. D., Lineberry C. G. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology. 1993 Nov;43(11):2284–2291. doi: 10.1212/wnl.43.11.2284. [DOI] [PubMed] [Google Scholar]
  9. McKee P. J., Blacklaw J., Friel E., Thompson G. G., Gillham R. A., Brodie M. J. Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients? Epilepsia. 1993 Sep-Oct;34(5):937–943. doi: 10.1111/j.1528-1157.1993.tb02115.x. [DOI] [PubMed] [Google Scholar]
  10. Meldrum B. S. Anatomy, physiology, and pathology of epilepsy. Lancet. 1990 Jul 28;336(8709):231–234. doi: 10.1016/0140-6736(90)91747-x. [DOI] [PubMed] [Google Scholar]
  11. Panayiotopoulos C. P., Ferrie C. D., Knott C., Robinson R. O. Interaction of lamotrigine with sodium valproate. Lancet. 1993 Feb 13;341(8842):445–445. doi: 10.1016/0140-6736(93)93048-6. [DOI] [PubMed] [Google Scholar]
  12. Pisani F., Di Perri R., Perucca E., Richens A. Interaction of lamotrigine with sodium valproate. Lancet. 1993 May 8;341(8854):1224–1224. doi: 10.1016/0140-6736(93)91062-q. [DOI] [PubMed] [Google Scholar]
  13. Proceedings of the Association of British Neurologists and the Liaison Psychiatry Group, Royal College of Psychiatrists. April 2-3, 1992. Abstracts. J Neurol Neurosurg Psychiatry. 1992 May;55(5):416–423. doi: 10.1136/jnnp.55.5.416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sander J. W., Patsalos P. N., Oxley J. R., Hamilton M. J., Yuen W. C. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res. 1990 Aug;6(3):221–226. doi: 10.1016/0920-1211(90)90077-9. [DOI] [PubMed] [Google Scholar]
  15. Schapel G. J., Beran R. G., Vajda F. J., Berkovic S. F., Mashford M. L., Dunagan F. M., Yuen W. C., Davies G. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry. 1993 May;56(5):448–453. doi: 10.1136/jnnp.56.5.448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Stewart J., Hughes E., Reynolds E. H. Lamotrigine for generalised epilepsies. Lancet. 1992 Nov 14;340(8829):1223–1223. doi: 10.1016/0140-6736(92)92922-3. [DOI] [PubMed] [Google Scholar]
  17. Warner T., Patsalos P. N., Prevett M., Elyas A. A., Duncan J. S. Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Res. 1992 Apr;11(2):147–150. doi: 10.1016/0920-1211(92)90049-y. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES